<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624790</url>
  </required_header>
  <id_info>
    <org_study_id>CIR 320</org_study_id>
    <nct_id>NCT03624790</nct_id>
  </id_info>
  <brief_title>Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers</brief_title>
  <official_title>Phase I, Open Label, Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, infectivity and replication, and
      immunogenicity of a recombinant respiratory syncytial virus (rRSV A/Maryland/001/11)
      challenge virus administered intranasally to healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, infectivity and replication, and immunogenicity of a
      recombinant respiratory syncytial virus (rRSV A/Maryland/001/11) challenge virus administered
      intranasally to healthy adults.

      Participants will be admitted to the inpatient isolation unit and will receive a single dose
      of 10^5 plaque forming units (PFUs) of rRSV A/Maryland/001/11, delivered intranasally on Day
      0. Participants will be enrolled outside of the RSV season between April 1 and October 31.

      Participants will remain in the inpatient isolation unit for a minimum of 8 days after the
      challenge and will be discharged after two RSV reverse transcription polymerase chain
      reaction (RT-PCR) results lower than 3 Log10 genome equivalents per mL of nasal wash.

      Upon discharge from the inpatient unit, participants will attend outpatient visits on Days 10
      (if previously discharged), 28, and 56. These study visits may include physical examinations,
      blood collection, and nasal washes. At 6 months, there will be a follow-up phone contact to
      assess for any new chronic conditions or serious health events/hospitalizations.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of challenge virus-related solicited signs and symptoms</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of challenge virus-related solicited signs and symptoms</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of AEs</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants infected with rRSV A/Maryland/001/11 challenge virus</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Defined as recovery of challenge virus from nasal wash, and/or detection of virus in nasal wash by real-time reverse transcription polymerase chain reaction (rRT-PCR), and/or a greater than or equal to 2.5-fold rise in serum neutralizing antibody titer to RSV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal wash virus titers of challenge virus shed</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Measured by plaque titration and rRT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of days challenge virus was shed</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Measured by plaque titration and rRT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titer of serum immunoglobulin G (IgG) antibodies to the RSV F protein</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Measured by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum neutralizing antibody titer to RSV</measure>
    <time_frame>Measured through Day 56</time_frame>
    <description>Measured by plaque reduction assay</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: rRSV A/Maryland/001/11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rRSV A/Maryland/001/11</intervention_name>
    <description>10^5 PFU; delivered intranasally</description>
    <arm_group_label>Group 1: rRSV A/Maryland/001/11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and non-pregnant females between 18 years and 50 years of age, inclusive.

          -  General good health, without significant medical illness, physical examination
             findings, or significant laboratory abnormalities as determined by the investigator.

          -  Demonstrates comprehension of the protocol procedures and knowledge of RSV illness by
             passing a written comprehension examination (pass grade greater than or equal to 70%).

          -  Available for the duration of the trial.

          -  Willingness to participate in the study and stay confined to the inpatient unit for
             the required duration as evidenced by signing the informed consent document.

          -  Female subjects of childbearing potential must agree to have used effective birth
             control methods beginning at least one month prior to challenge, and continuing with
             'per label/fully effective use' for the chosen method for the duration of the study,
             from amongst these:

               -  pharmacologic/hormonal contraceptives, including oral, parenteral, subcutaneous,
                  and transcutaneous delivery;

               -  condoms or diaphragm with spermicide;

               -  intrauterine device;

               -  absolute abstinence from heterosexual intercourse as a matter of normal preferred
                  lifestyle;

               -  or must be surgically sterile, or must be 50 years of age AND have had no menses
                  at all for at least one full year.

               -  All females must provide samples for urine and serum pregnancy testing prior to
                  enrollment, prior to challenge, as well as a statement of menstrual history, at
                  each study contact throughout the study, and report if they may be pregnant
                  immediately.

          -  Willingness to refrain from blood donation during their participation in the study.

          -  Willingness to refrain from receiving vaccines or other investigational products
             during the first 2 months of the study after enrollment.

          -  Willingness to follow admission and isolation requirements for the indicated duration
             per protocol.

        Exclusion Criteria:

          -  Subject who was previously challenged with RSV in any study, or previously
             participated in an RSV vaccine study.

          -  Female subject who is pregnant or lactating OR planning to become pregnant in the
             timeframe that begins 30 days prior to the inoculation and ends 30 days after
             inoculation. Pregnancy is determined by a positive test for human chorionic
             gonadotropin (Î²-HCG test).

          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,
             rheumatologic, autoimmune, or renal disease by history, physical examination, and/or
             laboratory studies.

          -  Behavioral or cognitive impairment or psychiatric disease that in the opinion of the
             investigator affects the ability of the subject to understand and cooperate with the
             study protocol.

          -  A history of asthma within the past 5 years, or a current diagnosis of asthma or
             reactive airway disease associated with exercise, seasonal hay fever or allergic
             rhinitis.

          -  Presence of any febrile illness or symptoms suggestive of a respiratory infection
             within 2 weeks prior to inoculation.

          -  Use of systemic or nasal steroid preparations or immunosuppressive drugs within 30
             days prior to challenge. Topical steroid preparations are permitted.

          -  Inhaled bronchodilator or inhaled steroid use within the last year or use after upper
             respiratory tract infections within the last 5 years.

          -  Current or past (in the last 4 weeks) use of i.n. medications (including steroids,
             decongestants, or hormonal medications), or planning to use them within 28 days of
             study challenge

          -  Positive urine drug toxicology test for the presence of amphetamine, barbiturates,
             opiates, phencyclidine, benzodiazepines, methadone or cocaine metabolites.

          -  Evidence of current alcohol or illicit drug abuse or addiction.

          -  Other condition that in the opinion of the investigator would jeopardize the safety or
             rights of a subject participating in the trial or would render the subject unable to
             comply with the protocol.

          -  History of anaphylaxis.

          -  Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory tests for human
             immunodeficiency virus (HIV).

          -  Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for
             hepatitis C virus (HCV).

          -  Positive hepatitis B virus surface antigen (HBsAg) by ELISA.

          -  Known immunodeficiency syndrome.

          -  Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to
             inoculation with RSV challenge and planned receipt within 60 days after challenge.

          -  History of a surgical splenectomy.

          -  Receipt of blood or blood-derived products (including immunoglobulin [Ig]) within 6
             months prior to study inoculation.

          -  Current routine (at least once weekly) smoking or vaping of a tobacco product or
             marijuana.

               -  The decision to exclude a potential subject is determined by medical history and
                  a clinician's clinical judgment based on the physical examination.

          -  Receipt of any investigational vaccine or drug within 30 days prior or planned use
             within 60 days after study inoculation.

          -  Body mass index (BMI) less than 18.5 or greater than 37.5.

          -  Shared household, works closely with, or has routine contact with a child (children)
             less than 2 years of age or with immunocompromised individual(s), adults with
             significant cardiopulmonary disease, persons with significant asthma,
             institutionalized elderly or elderly with functional disability or any other
             individual that, in the judgment of the Principal Investigator (PI), might be at
             increased risk for complications if exposed to RSV.

          -  Any significant abnormality of the nose or nasopharynx, including recurrent epistaxis
             and including nasal or sinus surgery.

          -  History of Bell's palsy.

          -  Unwillingness to have nasopharyngeal (NP) or blood samples saved for future
             respiratory virus research.

          -  Serum RSV neutralizing antibody titers greater than or equal to 320.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kawsar Talaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03624790/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

